We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Vintage legal loophole comes back to haunt drugmaker; City crypto converts in demand; and COP26 takes to the water
Trial results come month after UK terminated contract with French company
Clearly, enough shareholders must accept lowball offers to make the effort worthwhile
Advances by Merck and AstraZeneca raise hopes of bringing more treatments to market
UK pharma group to commercialise 26 drug targets using technology proved by Covid vaccines
Government officials say using different jabs for third doses should provide better protection
Pharma group agrees to provide remaining doses by next March
Clinical trial shows drug significantly reduces development of symptomatic Covid compared with placebo
Pharmaceutical industry and health officials lock horns over intellectual property waivers for Covid-19 jabs
Pharma group’s chief executive Pascal Soriot cool on need for booster shots
Anglo-Swedish drugmaker pledges to supply 5m-6m doses as Thailand battles record wave of infections
The recent court decision on the rights and wrongs of delayed deliveries was a shock for its subtlety
Pharma group avoids billions in fines but court acknowledges ‘serious breach’ of contracts
New infections mean 30 to 39-year-olds at more risk from Covid than vaccine-related blood clots, FT analysis shows
The drugmaker has found good intentions only intensify public scrutiny
Phase 3 stage shows drug not significantly more effective than placebo
AstraZeneca’s vaccine has saved many thousands of lives. But rare side-effects, and, relative to competitors, lower efficacy against new variants have given it an uncertain outlook. Coupled with a multibillion-euro lawsuit over delivery shortfalls, the UK pharma group’s future role in the ongoing battle against Covid-19 is under scrutiny
Campaign built around Oxford/AstraZeneca jab manufactured by company owned by king
Plus, Olympics sponsors ask for delay and executives should listen to climate activists
Lynparza shown to reduce recurrence rates, while Novartis to unveil new type of radiotherapy
Dose expiry dates and delayed international deliveries mean some jabs arrive too late to be used
Hit by a multibillion-euro lawsuit and rare side-effects, the jab that was going to save the world has an uncertain outlook
German researchers say side effect is caused by adenovirus vector and can be fixed
Brussels wants penalty of €10 a dose a day if pharma company does not supply more, lawyer tells court
International Edition
